Off-Label Obesity Treatment Alternatives for Complicated Patients (Recorded 3 CME/CE)

CME/CE Expiration Date: 4/25/2024* 

*The expiration date listed above is the last day CME/CE credit can be claimed for these specific presentations.

Description: 

Obesity prevalence is at worldwide epidemic levels, and behind cigarette smoking, obesity is the second leading cause of preventable deaths. Interventions directed toward improving nutrition, increasing physical activity, and changing eating behaviors can be effective treatments for obesity, but long -term benefits are often countered by neuro-hormonally activated homeostatic mechanisms that eventually lead to weight regain. Anti-obesity pharmacologic agents are often effective in combating the internal drives that increase appetite and contribute to obesity as well as those associated with weight regain. Despite the prevalence and deadly consequences of obesity, there are currently only four FDA approved anti-obesity medications for long -term use and four older sympathomimetic agents approved only three month’s treatment duration. Pharmacologic options for obesity treatment are further limited by other factors that include medication expense and lack of insurance coverage, concurrent medical conditions, drug interactions, adverse drug effects, and individual lack of therapeutic response in some individuals.  

Fortunately, there are options that are not FDA approved (off-label) that are generally safe and efficacious for obesity treatment backed by clinical experience and medical literature. This educational series will focus on safe and efficacious obesity treatment in challenging patients when FDA approved therapeutic agents are not an option. 

With disease management, the weight-gain potential of medications is often not considered when choosing pharmacotherapy options. Many commonly used medications associated with weight gain have alternatives with weight neutral or weight losing effects.  Shifting medication choices from weight positive to weight neutral or negative choices can be an effective means of facilitating weight loss. 

 

Accreditation: 

The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Medicine Association designates this enduring material for a maximum of 3 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Do No Harm – Alternatives to Weight Promoting Medications

    Includes Credits

    Donna Ryan, MD

    CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

    Description: 

    A number of commonly used medications are associated with weight gain. This session will review commonly used medications that promote weight gain. Alternatives will be discussed in case-based scenarios.

    Accreditation:       

    The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

    The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

  • Thinking Outside the Box for Obesity Medication Treatment

    Includes Credits

    Deborah Bade Horn, DO, MPH, MFOMA

    CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

    Description: 

    With limited options and cost limitations for prescribing anti-obesity medications, experienced obesity medicine specialists recognize the importance of off-label use of medication for obesity treatment. This session will briefly review medications that are known to aid in weight loss but lack FDA approval for use in obesity treatment. The session will also include discussion of long-term use of medications that are only approved by the FDA for short-term use. The program will include an interactive discussion of a number of patient scenarios where alternative medications can be considered for obesity treatment.

    Accreditation:       

    The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

    The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

  • Optimizing use of FDA Approved Anti-obesity Medications

    Includes Credits

    Craig Primack, MD, FACP, FAAP, Dipl. ABOM

    CME/CE Expiration Date: 4/25/2024* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

    Description: 

    This session provides a brief overview of FDA-approved anti-obesity medications (AOM’s). The session includes a series of case presentations exploring medication options in specific patient scenarios.

    Accreditation:       

    The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

    The Obesity Medicine Association designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.